This company has been marked as potentially delisted and may not be actively trading. FS Development (FSDC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock FSDC vs. AMRX, HCM, XENE, MIRM, OGN, APLS, ARWR, AAPG, NAMS, and LGNDShould you be buying FS Development stock or one of its competitors? The main competitors of FS Development include Amneal Pharmaceuticals (AMRX), HUTCHMED (HCM), Xenon Pharmaceuticals (XENE), Mirum Pharmaceuticals (MIRM), Organon & Co. (OGN), Apellis Pharmaceuticals (APLS), Arrowhead Pharmaceuticals (ARWR), Ascentage Pharma Group International (AAPG), NewAmsterdam Pharma (NAMS), and Ligand Pharmaceuticals (LGND). These companies are all part of the "medical" sector. FS Development vs. Amneal Pharmaceuticals HUTCHMED Xenon Pharmaceuticals Mirum Pharmaceuticals Organon & Co. Apellis Pharmaceuticals Arrowhead Pharmaceuticals Ascentage Pharma Group International NewAmsterdam Pharma Ligand Pharmaceuticals FS Development (NASDAQ:FSDC) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, community ranking, profitability, valuation, risk, earnings, media sentiment and dividends. Which has higher earnings and valuation, FSDC or AMRX? FS Development has higher earnings, but lower revenue than Amneal Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFS DevelopmentN/AN/AN/AN/AN/AAmneal Pharmaceuticals$2.83B0.79-$83.99M-$0.04-179.00 Is FSDC or AMRX more profitable? FS Development has a net margin of 0.00% compared to Amneal Pharmaceuticals' net margin of -6.88%. FS Development's return on equity of 0.00% beat Amneal Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets FS DevelopmentN/A N/A N/A Amneal Pharmaceuticals -6.88%-346.26%4.85% Do analysts prefer FSDC or AMRX? Amneal Pharmaceuticals has a consensus price target of $11.50, indicating a potential upside of 60.61%. Given Amneal Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Amneal Pharmaceuticals is more favorable than FS Development.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score FS Development 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Amneal Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor FSDC or AMRX? Amneal Pharmaceuticals received 20 more outperform votes than FS Development when rated by MarketBeat users. CompanyUnderperformOutperformFS DevelopmentN/AN/AAmneal PharmaceuticalsOutperform Votes2095.24% Underperform Votes14.76% Does the media prefer FSDC or AMRX? In the previous week, Amneal Pharmaceuticals had 5 more articles in the media than FS Development. MarketBeat recorded 5 mentions for Amneal Pharmaceuticals and 0 mentions for FS Development. Amneal Pharmaceuticals' average media sentiment score of 1.47 beat FS Development's score of 0.00 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment FS Development Neutral Amneal Pharmaceuticals Positive Do institutionals & insiders have more ownership in FSDC or AMRX? 89.8% of FS Development shares are held by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 26.6% of Amneal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummaryAmneal Pharmaceuticals beats FS Development on 9 of the 12 factors compared between the two stocks. Get FS Development News Delivered to You Automatically Sign up to receive the latest news and ratings for FSDC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FSDC vs. The Competition Export to ExcelMetricFS DevelopmentPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$592.88M$6.46B$5.34B$8.30BDividend YieldN/A2.63%5.27%4.11%P/E RatioN/A8.4426.9619.59Price / SalesN/A258.50398.81136.02Price / CashN/A65.8538.3234.64Price / BookN/A6.416.774.50Net IncomeN/A$143.95M$3.24B$248.60M FS Development Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FSDCFS DevelopmentN/A$47.37-1.4%N/A+42.0%$592.88MN/A0.00N/AAMRXAmneal Pharmaceuticals3.1699 of 5 stars$7.50-1.3%$11.50+53.3%+11.0%$2.32B$2.83B-11.037,600HCMHUTCHMED2.4481 of 5 stars$13.14-5.6%$19.00+44.6%-28.5%$2.29B$630.20M0.001,760News CoveragePositive NewsAnalyst DowngradeGap DownXENEXenon Pharmaceuticals3.4013 of 5 stars$29.60-17.4%$54.80+85.1%-22.5%$2.27B$9.43M-10.50210Positive NewsAnalyst DowngradeHigh Trading VolumeMIRMMirum Pharmaceuticals4.0529 of 5 stars$45.27-0.7%$60.64+33.9%+79.2%$2.24B$379.25M-22.41140News CoveragePositive NewsAnalyst RevisionOGNOrganon & Co.4.7492 of 5 stars$8.43-3.2%$18.00+113.5%-58.6%$2.19B$6.29B2.5310,000Trending NewsGap DownHigh Trading VolumeAPLSApellis Pharmaceuticals4.1823 of 5 stars$17.28-1.4%$41.37+139.4%-57.1%$2.17B$775.84M-8.51770Analyst ForecastGap UpARWRArrowhead Pharmaceuticals3.5185 of 5 stars$15.28+9.4%$42.13+175.7%-39.2%$2.10B$2.50M-2.96400News CoveragePositive NewsAnalyst ForecastAnalyst RevisionGap UpHigh Trading VolumeAAPGAscentage Pharma Group InternationalN/A$24.04-0.7%N/AN/A$2.09B$980.65M0.00600News CoverageNAMSNewAmsterdam Pharma2.6346 of 5 stars$18.75-2.4%$43.00+129.3%-6.4%$2.06B$45.56M-9.974News CoveragePositive NewsAnalyst DowngradeLGNDLigand Pharmaceuticals4.3155 of 5 stars$105.63-0.7%$146.14+38.4%+17.6%$2.04B$181.49M42.0880Positive News Related Companies and Tools Related Companies Amneal Pharmaceuticals Competitors HUTCHMED Competitors Xenon Pharmaceuticals Competitors Mirum Pharmaceuticals Competitors Organon & Co. Competitors Apellis Pharmaceuticals Competitors Arrowhead Pharmaceuticals Competitors Ascentage Pharma Group International Competitors NewAmsterdam Pharma Competitors Ligand Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FSDC) was last updated on 5/25/2025 by MarketBeat.com Staff From Our PartnersGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FS Development Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share FS Development With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
